Surgery for Obesity and Related Diseases最新文献

英文中文

SOARD Category 1 CME Credit Featured Articles, Volume 21, March 2025

IF 3.5 3区医学 Q1 SURGERY

Surgery for Obesity and Related Diseases

Pub Date : 2025-02-06 DOI: 10.1016/j.soard.2025.01.001

引用次数: 0

Cartoon

IF 3.5 3区医学 Q1 SURGERY

Surgery for Obesity and Related Diseases

Pub Date : 2025-02-06 DOI: 10.1016/j.soard.2025.01.006

引用次数: 0

Evaluation of gastric content in fasting patient during semaglutide use: an observational study 一项观察性研究：评估使用塞马鲁肽期间空腹患者的胃内容物。

IF 3.5 3区医学 Q1 SURGERY

Surgery for Obesity and Related Diseases

Pub Date : 2025-02-01 DOI: 10.1016/j.soard.2024.08.039

Veronica Neves Fialho Queiroz M.D., Ph.D. , Priscila Mina Falsarella M.D., Ph.D. , Renato Carneiro de Freitas Chaves M.D., Ph.D. , Miguel Jose Francisco Neto M.D., Ph.D. , João Manoel Silva Jr. M.D., Ph.D. , Guilherme Freitas Araújo M.D. , Flávio Takaoka M.D., Ph.D. , Flávia Julie do Amaral Pfeilsticker M.D., Ms.C. , Guilherme Falleiros Mendes M.D. , Rodrigo Gobbo Garcia M.D., Ph.D.

Background

The evident influence of GLP-1 agonists as semaglutide on gastric emptying even in adherence to recommended fasting protocols instigates debates.

Objective

To investigate the effect of semaglutide on gastric content by gastric ultrasonography in volunteers.

Setting

Private hospital.

Methods

The present study is an observational, cross-sectional, and single-center study. We included 30 consecutive volunteers aged ≥18 years who had undergone a minimum fasting period of 8 hours for solid foods and 2 hours for clear, residue-free liquids. The intervention group consisted of 15 volunteers who had used semaglutide within the last 7 days, whereas the control group consisted of 15 volunteers who had never used semaglutide. The main objective was to determine whether the stomach was full or not.

Results

Between June 2023 and August 2023, a total of 30 adult volunteers were included in the study, and no participant was excluded. The semaglutide group exhibited a higher prevalence of full stomach (11 of 15 [73%] versus 1 of 15 [7%], P < .001; adjusted to age P = .003). The semaglutide group also exhibited a higher prevalence of early satiety (10 of 15 [67%] versus 0 of 15 [0%], P < .001), loss of appetite (10 of 15 [67%] versus 0 of 15 [0%], P < .001), gastric fullness (8 of 15 [53%] versus 0 of 15 [0%], P = .002), and nausea (7 of 15 [47%] versus 1 of 15 [7%], P = .035). Additionally, there is no case in the semaglutide group with no gastric contents.

Conclusions

The use of semaglutide is associated with full stomach even after appropriate overnight fasting. Semaglutide is also associated with increased gastrointestinal symptoms such as loss of appetite, early satiety, gastric fullness, and nausea.

背景：GLP-1激动剂如塞马鲁肽对胃排空的明显影响，即使是在遵守推荐的空腹方案的情况下，也会引起争论：通过胃超声波检查志愿者的胃内容物，研究塞马鲁肽对胃内容物的影响：地点：私立医院：本研究是一项观察性、横断面和单中心研究。我们连续纳入了 30 名年龄≥18 岁的志愿者，他们至少禁食 8 小时固体食物，禁食 2 小时无渣透明液体。干预组由 15 名在过去 7 天内使用过塞马鲁肽的志愿者组成，而对照组由 15 名从未使用过塞马鲁肽的志愿者组成。主要目的是确定胃部是否饱满：结果：在 2023 年 6 月至 2023 年 8 月期间，共有 30 名成年志愿者参与了研究，没有人被排除在外。结果表明，塞马鲁肽组的饱腹率更高（15人中有11人[73%]，而15人中有1人[7%]，P < .001；根据年龄调整后，P = .003）。塞马鲁肽组还表现出更高的早饱率（15 例中有 10 例[67%]，15 例中有 0 例[0%]，P < .001）、食欲不振率（15 例中有 10 例[67%]，15 例中有 0 例[0%]，P < .001）、胃部饱胀率（15 例中有 8 例[53%]，15 例中有 0 例[0%]，P = .002）和恶心率（15 例中有 7 例[47%]，15 例中有 1 例[7%]，P = .035）。此外，塞马鲁肽组中没有出现无胃内容物的病例：结论：使用塞马鲁肽时，即使适当空腹过夜也会出现饱腹感。结论：即使在适当的隔夜禁食后，使用塞马鲁肽也会导致胃部饱胀。塞马鲁肽还会增加胃肠道症状，如食欲不振、早饱、胃部饱胀和恶心。

{"title":"Evaluation of gastric content in fasting patient during semaglutide use: an observational study","authors":"Veronica Neves Fialho Queiroz M.D., Ph.D. , Priscila Mina Falsarella M.D., Ph.D. , Renato Carneiro de Freitas Chaves M.D., Ph.D. , Miguel Jose Francisco Neto M.D., Ph.D. , João Manoel Silva Jr. M.D., Ph.D. , Guilherme Freitas Araújo M.D. , Flávio Takaoka M.D., Ph.D. , Flávia Julie do Amaral Pfeilsticker M.D., Ms.C. , Guilherme Falleiros Mendes M.D. , Rodrigo Gobbo Garcia M.D., Ph.D.","doi":"10.1016/j.soard.2024.08.039","DOIUrl":"10.1016/j.soard.2024.08.039","url":null,"abstract":"<div><h3>Background</h3><div>The evident influence of GLP-1 agonists as semaglutide on gastric emptying even in adherence to recommended fasting protocols instigates debates.</div></div><div><h3>Objective</h3><div>To investigate the effect of semaglutide on gastric content by gastric ultrasonography in volunteers.</div></div><div><h3>Setting</h3><div>Private hospital.</div></div><div><h3>Methods</h3><div>The present study is an observational, cross-sectional, and single-center study. We included 30 consecutive volunteers aged ≥18 years who had undergone a minimum fasting period of 8 hours for solid foods and 2 hours for clear, residue-free liquids. The intervention group consisted of 15 volunteers who had used semaglutide within the last 7 days, whereas the control group consisted of 15 volunteers who had never used semaglutide. The main objective was to determine whether the stomach was full or not.</div></div><div><h3>Results</h3><div>Between June 2023 and August 2023, a total of 30 adult volunteers were included in the study, and no participant was excluded. The semaglutide group exhibited a higher prevalence of full stomach (11 of 15 [73%] versus 1 of 15 [7%], <em>P</em> < .001; adjusted to age <em>P</em> = .003). The semaglutide group also exhibited a higher prevalence of early satiety (10 of 15 [67%] versus 0 of 15 [0%], <em>P</em> < .001), loss of appetite (10 of 15 [67%] versus 0 of 15 [0%], <em>P</em> < .001), gastric fullness (8 of 15 [53%] versus 0 of 15 [0%], <em>P</em> = .002), and nausea (7 of 15 [47%] versus 1 of 15 [7%], <em>P</em> = .035). Additionally, there is no case in the semaglutide group with no gastric contents.</div></div><div><h3>Conclusions</h3><div>The use of semaglutide is associated with full stomach even after appropriate overnight fasting. Semaglutide is also associated with increased gastrointestinal symptoms such as loss of appetite, early satiety, gastric fullness, and nausea.</div></div>","PeriodicalId":49462,"journal":{"name":"Surgery for Obesity and Related Diseases","volume":"21 2","pages":"Pages 146-151"},"PeriodicalIF":3.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Statin use trajectories postbariatric surgery: a matched cohort analysis 减肥手术后他汀类药物的使用轨迹：匹配队列分析。

IF 3.5 3区医学 Q1 SURGERY

Surgery for Obesity and Related Diseases

Pub Date : 2025-02-01 DOI: 10.1016/j.soard.2024.08.043

Anyull D. Bohorquez Caballero M.D. , Elizabeth Wall-Wieler Ph.D. , Yuki Liu M.Sc. , Feibi Zheng M.D. , Michael A. Edwards M.D.

Background

Metabolic and bariatric surgery (MBS) is the most durable treatment of obesity and can reduce statin use.

Objective

We compare statin use trajectories in patients with and without MBS.

Methods

Adults with a body mass index ≥ 35kg/m² were identified using a U.S. employer-based retrospective claims database. Individuals who had MBS were matched 1:1 with those who did not. Trajectories of statin use were stratified by statin use in the year before the index date and examined in the 2 years after the index date.

Setting

University Hospital.

Results

Sixteen thousand three hundred fifty-nine adults who had MBS and 16,359 matched adults who did not were analyzed. In both groups, 19.4% filled a statin prescription in the year before the index date. In the 2 years after the index date, individuals using statins remained similar at 20% (year 1) and 19% (year 2) among those who didn’t have an MBS and decreased to 12.5% (year 1) and 9.3% (year 2) in the MBS cohort. Among baseline statin users, 35.4% of non-MBS and 60.4% of the MBS cohort stopped using statins within 2 years of the index date. Among statin naïve individuals at baseline, 9.6% of the non-MBS cohort started using statins within 2 years of the index date, compared to 2.6% of those who had MBS.

Conclusions

MBS results in a significant discontinuation of statins among baseline users, and significantly decreased the initiation of medications among individuals who were statin naive at baseline. This demonstrates that MBS is both a treatment and preventative measure for dyslipidemia.

背景：代谢和减肥手术（MBS）是肥胖症最持久的治疗方法，可减少他汀类药物的使用：我们比较了接受和未接受代谢与减肥手术的患者使用他汀类药物的轨迹：方法：我们通过基于美国雇主的回顾性索赔数据库确定了体重指数≥ 35kg/m2 的成年人。患有 MBS 的患者与未患有 MBS 的患者进行 1:1 匹配。根据指数日期前一年他汀类药物的使用情况对他汀类药物的使用轨迹进行分层，并对指数日期后两年的他汀类药物使用情况进行检查：地点：大学医院：分析了 16,359 名患有 MBS 的成年人和 16,359 名未患有 MBS 的匹配成年人。两组中均有 19.4% 的人在指数日期前一年开过他汀类药物处方。在指数日期后的两年中，没有进行 MBS 的人群中使用他汀类药物的比例仍然相似，分别为 20%（第一年）和 19%（第二年），而在 MBS 群体中，使用他汀类药物的比例则分别降至 12.5%（第一年）和 9.3%（第二年）。在基线他汀类药物使用者中，35.4% 的非 MBS 和 60.4% 的 MBS 群体在指数日期后的 2 年内停止使用他汀类药物。在基线他汀类药物新使用者中，9.6%的非MBS队列在指数日期后2年内开始使用他汀类药物，而在MBS队列中，这一比例仅为2.6%：结论：他汀类药物基线使用者停用他汀类药物的情况非常明显，而他汀类药物基线使用者开始使用他汀类药物的情况则明显减少。这表明，MBS 既能治疗血脂异常，又能预防血脂异常。

{"title":"Statin use trajectories postbariatric surgery: a matched cohort analysis","authors":"Anyull D. Bohorquez Caballero M.D. , Elizabeth Wall-Wieler Ph.D. , Yuki Liu M.Sc. , Feibi Zheng M.D. , Michael A. Edwards M.D.","doi":"10.1016/j.soard.2024.08.043","DOIUrl":"10.1016/j.soard.2024.08.043","url":null,"abstract":"<div><h3>Background</h3><div>Metabolic and bariatric surgery (MBS) is the most durable treatment of obesity and can reduce statin use.</div></div><div><h3>Objective</h3><div>We compare statin use trajectories in patients with and without MBS.</div></div><div><h3>Methods</h3><div>Adults with a body mass index ≥ 35kg/m<sup>2</sup> were identified using a U.S. employer-based retrospective claims database. Individuals who had MBS were matched 1:1 with those who did not. Trajectories of statin use were stratified by statin use in the year before the index date and examined in the 2 years after the index date.</div></div><div><h3>Setting</h3><div>University Hospital.</div></div><div><h3>Results</h3><div>Sixteen thousand three hundred fifty-nine adults who had MBS and 16,359 matched adults who did not were analyzed. In both groups, 19.4% filled a statin prescription in the year before the index date. In the 2 years after the index date, individuals using statins remained similar at 20% (year 1) and 19% (year 2) among those who didn’t have an MBS and decreased to 12.5% (year 1) and 9.3% (year 2) in the MBS cohort. Among baseline statin users, 35.4% of non-MBS and 60.4% of the MBS cohort stopped using statins within 2 years of the index date. Among statin naïve individuals at baseline, 9.6% of the non-MBS cohort started using statins within 2 years of the index date, compared to 2.6% of those who had MBS.</div></div><div><h3>Conclusions</h3><div>MBS results in a significant discontinuation of statins among baseline users, and significantly decreased the initiation of medications among individuals who were statin naive at baseline. This demonstrates that MBS is both a treatment and preventative measure for dyslipidemia.</div></div>","PeriodicalId":49462,"journal":{"name":"Surgery for Obesity and Related Diseases","volume":"21 2","pages":"Pages 152-157"},"PeriodicalIF":3.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142396452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patients experience with preoperative use of anti-obesity medications and associations with bariatric surgery expectations 患者术前使用抗肥胖药物的经验以及与减肥手术期望值的关联。

IF 3.5 3区医学 Q1 SURGERY

Surgery for Obesity and Related Diseases

Pub Date : 2025-02-01 DOI: 10.1016/j.soard.2024.08.041

Jason M. Samuels M.D. , Mayur B. Patel M.D., M.P.H., F.A.C.S. , Christianne L. Roumie M.D., M.P.H. , Wesley Self M.D., M.P.H. , Luke Funk M.D., M.P.H. , Matthew D. Spann M.D., M.M.H.C. , Kevin D. Niswender M.D., Ph.D.

Background

Few studies have investigated the use of anti-obesity medications (AOMs) before bariatric surgery and how prior use impacts patients’ goals and expectations for surgery.

Objectives

This study investigated associations between patients’ experiences with AOMs and weight loss expectations before bariatric surgery.

Settings

Single tertiary university hospital.

Methods

Patients were electronically surveyed with a 31-item questionnaire via email or the patient portal with a primary predictor variable of AOMs presurgery. Outcomes included degree of weight loss and weight regain and motivation for seeking surgery.

Results

A total of 346 persons were invited to complete the survey; 112 surveys (32.4%) were completed, with 7 excluded because of not answering the AOM question. 73% reported AOM use. Among those who took AOMs before seeking bariatric surgery, average weight loss was 13 kg (SD 10) corresponding to a 4.4-kg/m² decrease in BMI. Of past AOM recipients, 87% reported weight regain on stopping AOMs. Average weight regain was 18 kg (SD 13; 126% increase). Patients reported improved longevity and quality of life as motivation for seeking surgery, with AOM use history having no effect. Subjects reported an average weight loss goal of 65.8 kg (39% of baseline weight) from bariatric surgery.

Conclusions

AOMs were commonly used in those seeking bariatric surgery, but motivation for surgery did not differ by AOM use history. Motivations were most often related to goals for better overall health.

背景：很少有研究调查减肥手术前使用抗肥胖药物（AOMs）的情况，以及之前的使用情况如何影响患者的手术目标和期望：本研究调查了患者在减肥手术前使用抗肥胖药物的经历与减肥期望之间的关联：方法：对患者进行电子问卷调查：通过电子邮件或患者门户网站对患者进行电子问卷调查，问卷共31项，主要预测变量为术前AOMs。结果包括体重减轻和恢复程度以及寻求手术的动机：共有346人受邀完成调查，其中112人（32.4%）完成了调查，7人因未回答AOM问题而被排除在外。73%的人报告使用过AOM。在寻求减肥手术前服用过AOM的人中，平均体重减轻了13公斤（标准差10），体重指数（BMI）下降了4.4公斤/平方米。在过去服用过AOM的患者中，有87%的人表示在停用AOM后体重会反弹。平均体重增加了18公斤（标准差为13；增加了126%）。患者表示，他们寻求手术治疗的动机是为了延长寿命和提高生活质量，而使用AOM的历史并无影响。受试者称减肥手术的平均减重目标为65.8公斤（基线体重的39%）：结论：寻求减肥手术的人通常会使用AOM，但手术动机并不因使用AOM的历史而不同。手术动机通常与改善整体健康的目标有关。

{"title":"Patients experience with preoperative use of anti-obesity medications and associations with bariatric surgery expectations","authors":"Jason M. Samuels M.D. , Mayur B. Patel M.D., M.P.H., F.A.C.S. , Christianne L. Roumie M.D., M.P.H. , Wesley Self M.D., M.P.H. , Luke Funk M.D., M.P.H. , Matthew D. Spann M.D., M.M.H.C. , Kevin D. Niswender M.D., Ph.D.","doi":"10.1016/j.soard.2024.08.041","DOIUrl":"10.1016/j.soard.2024.08.041","url":null,"abstract":"<div><h3>Background</h3><div>Few studies have investigated the use of anti-obesity medications (AOMs) before bariatric surgery and how prior use impacts patients’ goals and expectations for surgery.</div></div><div><h3>Objectives</h3><div>This study investigated associations between patients’ experiences with AOMs and weight loss expectations before bariatric surgery.</div></div><div><h3>Settings</h3><div>Single tertiary university hospital.</div></div><div><h3>Methods</h3><div>Patients were electronically surveyed with a 31-item questionnaire via email or the patient portal with a primary predictor variable of AOMs presurgery. Outcomes included degree of weight loss and weight regain and motivation for seeking surgery.</div></div><div><h3>Results</h3><div>A total of 346 persons were invited to complete the survey; 112 surveys (32.4%) were completed, with 7 excluded because of not answering the AOM question. 73% reported AOM use. Among those who took AOMs before seeking bariatric surgery, average weight loss was 13 kg (SD 10) corresponding to a 4.4-kg/m<sup>2</sup> decrease in BMI. Of past AOM recipients, 87% reported weight regain on stopping AOMs. Average weight regain was 18 kg (SD 13; 126% increase). Patients reported improved longevity and quality of life as motivation for seeking surgery, with AOM use history having no effect. Subjects reported an average weight loss goal of 65.8 kg (39% of baseline weight) from bariatric surgery.</div></div><div><h3>Conclusions</h3><div>AOMs were commonly used in those seeking bariatric surgery, but motivation for surgery did not differ by AOM use history. Motivations were most often related to goals for better overall health.</div></div>","PeriodicalId":49462,"journal":{"name":"Surgery for Obesity and Related Diseases","volume":"21 2","pages":"Pages 109-114"},"PeriodicalIF":3.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142402541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evolution of treated obstructive sleep apneas syndrome after bariatric surgery: an observational retrospective study 减肥手术后阻塞性睡眠呼吸暂停综合征的演变：一项观察性回顾研究。

IF 3.5 3区医学 Q1 SURGERY

Surgery for Obesity and Related Diseases

Pub Date : 2025-02-01 DOI: 10.1016/j.soard.2024.08.038

Corentin Puech M.D. , Jérémie Thereaux M.D., Ph.D. , Francis Couturaud M.D., Ph.D. , Christophe Leroyer M.D., Ph.D. , Cécile Tromeur M.D., Ph.D. , Christophe Gut-Gobert M.D. , Charles Orione M.D. , Raphaël Le Mao M.D., Ph.D. , Cécile L’hévéder M.D.

Background

The resolution of obstructive sleep apneas syndrome (OSAS) following bariatric surgery appears to be promising for the majority of patients although this resolution does not necessarily exhibit a linear correlation with weight loss. Previous small-scale studies have pinpointed a younger age and preoperative weight under 100kg as predictive factors of OSAS improvement

Objectives

The primary objective was to evaluate the evolution of OSAS in patients treated with continuous positive airway pressure (CPAP). Additionally, we tried to identify potential predictive factors for OSAS improvement postsurgery.

Setting

Brest Hospital, France, University Hospital.

Methods

In this retrospective, observational study we analyzed a cohort of 44 patients who underwent bariatric surgery, between January 2015 and December 2021. Each patient underwent respiratory polygraphy (RP) or polysomnography (PSG) before and after the surgical procedure. We collected CPAP data (including effective pressure and adherence) before and during the 6 months following the intervention.

Results

Within the study population, 68.18% of patients exhibited improved OSAS, as defined as an apnea-hypopnea index of less than 15 per hour. A higher mean oxygen saturation prior to surgery emerged as the sole predictive factor for OSAS improvement. CPAP adherence and therapeutic pressure value, 2 rarely studied parameters, did not show significant difference between improved and nonimproved patients.

Conclusions

The rate of OSAS resolution after surgery is 68.18%, with only a higher mean oxygen saturation before surgery identified as a predictive factor for OSAS resolution.

背景：对大多数患者来说，减肥手术后阻塞性睡眠呼吸暂停综合征（OSAS）的缓解似乎很有希望，但这种缓解并不一定与体重下降呈线性相关。之前的小规模研究指出，年龄较小和术前体重低于 100 公斤是阻塞性睡眠呼吸暂停综合症好转的预测因素：主要目的是评估使用持续气道正压（CPAP）治疗的患者 OSAS 的演变情况。此外，我们还试图确定手术后 OSAS 改善的潜在预测因素：法国布列斯特医院，大学医院：在这项回顾性观察研究中，我们分析了 2015 年 1 月至 2021 年 12 月期间接受减肥手术的 44 名患者。每位患者在手术前后都接受了呼吸多导图（RP）或多导睡眠图（PSG）检查。我们收集了干预前和干预后 6 个月内的 CPAP 数据（包括有效压力和依从性）：在研究人群中，68.18% 的患者的 OSAS 状况有所改善，即每小时呼吸暂停-低通气指数低于 15。手术前较高的平均血氧饱和度是预测 OSAS 改善的唯一因素。坚持使用 CPAP 和治疗压力值这两个很少被研究的参数在病情好转和病情未好转的患者之间并无显著差异：手术后OSAS缓解率为68.18%，只有手术前平均血氧饱和度较高才是OSAS缓解的预测因素。

{"title":"Evolution of treated obstructive sleep apneas syndrome after bariatric surgery: an observational retrospective study","authors":"Corentin Puech M.D. , Jérémie Thereaux M.D., Ph.D. , Francis Couturaud M.D., Ph.D. , Christophe Leroyer M.D., Ph.D. , Cécile Tromeur M.D., Ph.D. , Christophe Gut-Gobert M.D. , Charles Orione M.D. , Raphaël Le Mao M.D., Ph.D. , Cécile L’hévéder M.D.","doi":"10.1016/j.soard.2024.08.038","DOIUrl":"10.1016/j.soard.2024.08.038","url":null,"abstract":"<div><h3>Background</h3><div>The resolution of obstructive sleep apneas syndrome (OSAS) following bariatric surgery appears to be promising for the majority of patients although this resolution does not necessarily exhibit a linear correlation with weight loss. Previous small-scale studies have pinpointed a younger age and preoperative weight under 100kg as predictive factors of OSAS improvement</div></div><div><h3>Objectives</h3><div>The primary objective was to evaluate the evolution of OSAS in patients treated with continuous positive airway pressure (CPAP). Additionally, we tried to identify potential predictive factors for OSAS improvement postsurgery.</div></div><div><h3>Setting</h3><div>Brest Hospital, France, University Hospital.</div></div><div><h3>Methods</h3><div>In this retrospective, observational study we analyzed a cohort of 44 patients who underwent bariatric surgery, between January 2015 and December 2021. Each patient underwent respiratory polygraphy (RP) or polysomnography (PSG) before and after the surgical procedure. We collected CPAP data (including effective pressure and adherence) before and during the 6 months following the intervention.</div></div><div><h3>Results</h3><div>Within the study population, 68.18% of patients exhibited improved OSAS, as defined as an apnea-hypopnea index of less than 15 per hour. A higher mean oxygen saturation prior to surgery emerged as the sole predictive factor for OSAS improvement. CPAP adherence and therapeutic pressure value, 2 rarely studied parameters, did not show significant difference between improved and nonimproved patients.</div></div><div><h3>Conclusions</h3><div>The rate of OSAS resolution after surgery is 68.18%, with only a higher mean oxygen saturation before surgery identified as a predictive factor for OSAS resolution.</div></div>","PeriodicalId":49462,"journal":{"name":"Surgery for Obesity and Related Diseases","volume":"21 2","pages":"Pages 127-134"},"PeriodicalIF":3.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142378758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Should GLP-1 agonists be considered an alternative or adjunct to pediatric metabolic and bariatric surgery? more questions than answers GLP-1激动剂是否应被视为儿科代谢和减肥手术的替代或辅助手段？

IF 3.5 3区医学 Q1 SURGERY

Surgery for Obesity and Related Diseases

Pub Date : 2025-02-01 DOI: 10.1016/j.soard.2024.10.018

Marc P. Michalsky M.D., M.B.A. , Claudia K. Fox M.D., M.P.H. , Janey S.A. Pratt M.D.

引用次数: 0

Roux-en-Y gastric bypass versus duodenal switch in patients with body mass index ≥50 kg/m2: a systematic review and meta-analysis 体重指数≥50 kg/m2 患者的 Roux-en-Y 胃旁路术与十二指肠转流术：系统综述和荟萃分析。

IF 3.5 3区医学 Q1 SURGERY

Surgery for Obesity and Related Diseases

Pub Date : 2025-02-01 DOI: 10.1016/j.soard.2024.08.042

Ali Esparham M.D. , Samira Roohi M.D. , Ali Mehri M.D. , Abolfazl Ghahramani M.D. , Hengameh Anari Moghadam M.D. , Zhamak Khorgami M.D., F.A.C.S.

Currently, there is no consensus on the best bariatric surgery type for patients with body mass index (BMI) ≥50 kg/m². This systematic review and meta-analysis aimed to compare outcomes of duodenal switch (DS) and Roux-en-Y gastric bypass (RYGB) in terms of weight loss, resolution of obesity-related comorbidities, and complications among patients with a BMI ≥50 kg/m². A systematic search was conducted across databases including PubMed, Embase, Scopus, and Web of Science to include studies that compared outcomes of DS and RYGB in patients with BMI ≥50 kg/m². A meta-analysis was carried out, alongside subgroup analyses based on the type of study and duration of follow-up. Twelve articles were included in this study (2678 patients, follow-up: 1–15 years). Patients with DS had 7.31 kg/m² higher BMI loss (95% CI: 5.59–9.03, P < .001) and 9.9% more total weight loss (95% CI: 4.47–15.28%, P < .001) compared with RYGB. The rate of complications, reoperation, mortality, and remission of comorbidities including diabetes, hypertension, dyslipidemia, and obstructive sleep apnea was not significantly different between DS and RYGB. Rate of malnutrition was 8.3% in the DS group compared with 1.2% in RYGB (OR: 5.53, 95% CI: 1.35–22.44, P = .02). In addition, 5.4% DS patients needed revisional surgery for malnutrition versus none in RYGB (OR: 6.1, 95% CI: 1.03–36.33, P = .05), and 24.6% of DS patients developed gallbladder disease needed cholecystectomy versus 4.5% after RYGB (OR: 6.36, 95% CI: 1.70–23.82, P = .01). DS leads to significantly higher BMI and total weight loss in patients with BMI ≥50 kg/m² but may be associated with a higher rate of major malnutrition and needed revisional surgery. These should be considered in surgical planning.

目前，关于体重指数（BMI）≥50 kg/m2患者的最佳减肥手术类型尚未达成共识。本系统综述和荟萃分析旨在比较十二指肠转位术（DS）和Roux-en-Y胃旁路术（RYGB）在体重指数（BMI）≥50 kg/m2患者的体重减轻、肥胖相关并发症的缓解和并发症方面的效果。我们在PubMed、Embase、Scopus和Web of Science等数据库中进行了系统性检索，以纳入对BMI≥50 kg/m2患者进行DS和RYGB疗效比较的研究。在进行荟萃分析的同时，还根据研究类型和随访时间进行了分组分析。本研究共纳入了12篇文章（2678名患者，随访时间：1-15年）。与 RYGB 相比，DS 患者的体重指数降低了 7.31 kg/m2（95% CI：5.59-9.03，P < .001），总重量降低了 9.9%（95% CI：4.47-15.28%，P < .001）。并发症发生率、再次手术率、死亡率以及糖尿病、高血压、血脂异常和阻塞性睡眠呼吸暂停等合并症的缓解率在 DS 和 RYGB 之间没有显著差异。DS 组营养不良率为 8.3%，而 RYGB 组为 1.2%（OR：5.53，95% CI：1.35-22.44，P = .02）。此外，5.4% 的 DS 患者因营养不良而需要再次手术，而 RYGB 患者无此需要（OR：6.1，95% CI：1.03-36.33，P = .05）；24.6% 的 DS 患者因胆囊疾病而需要进行胆囊切除术，而 RYGB 患者仅为 4.5%（OR：6.36，95% CI：1.70-23.82，P = .01）。DS 可使体重指数（BMI）≥50 kg/m2 的患者的体重指数和总重量明显增加，但可能与较高的严重营养不良率和需要再次手术有关。在制定手术计划时应考虑到这些因素。

{"title":"Roux-en-Y gastric bypass versus duodenal switch in patients with body mass index ≥50 kg/m2: a systematic review and meta-analysis","authors":"Ali Esparham M.D. , Samira Roohi M.D. , Ali Mehri M.D. , Abolfazl Ghahramani M.D. , Hengameh Anari Moghadam M.D. , Zhamak Khorgami M.D., F.A.C.S.","doi":"10.1016/j.soard.2024.08.042","DOIUrl":"10.1016/j.soard.2024.08.042","url":null,"abstract":"<div><div>Currently, there is no consensus on the best bariatric surgery type for patients with body mass index (BMI) ≥50 kg/m<sup>2</sup>. This systematic review and meta-analysis aimed to compare outcomes of duodenal switch (DS) and Roux-en-<span>Y</span> gastric bypass (RYGB) in terms of weight loss, resolution of obesity-related comorbidities, and complications among patients with a BMI ≥50 kg/m<sup>2</sup>. A systematic search was conducted across databases including PubMed, Embase, Scopus, and Web of Science to include studies that compared outcomes of DS and RYGB in patients with BMI ≥50 kg/m<sup>2</sup>. A meta-analysis was carried out, alongside subgroup analyses based on the type of study and duration of follow-up. Twelve articles were included in this study (2678 patients, follow-up: 1–15 years). Patients with DS had 7.31 kg/m<sup>2</sup> higher BMI loss (95% CI: 5.59–9.03, <em>P</em> < .001) and 9.9% more total weight loss (95% CI: 4.47–15.28%, <em>P</em> < .001) compared with RYGB. The rate of complications, reoperation, mortality, and remission of comorbidities including diabetes, hypertension, dyslipidemia, and obstructive sleep apnea was not significantly different between DS and RYGB. Rate of malnutrition was 8.3% in the DS group compared with 1.2% in RYGB (OR: 5.53, 95% CI: 1.35–22.44, <em>P</em> = .02). In addition, 5.4% DS patients needed revisional surgery for malnutrition versus none in RYGB (OR: 6.1, 95% CI: 1.03–36.33, <em>P</em> = .05), and 24.6% of DS patients developed gallbladder disease needed cholecystectomy versus 4.5% after RYGB (OR: 6.36, 95% CI: 1.70–23.82, <em>P</em> = .01). DS leads to significantly higher BMI and total weight loss in patients with BMI ≥50 kg/m<sup>2</sup> but may be associated with a higher rate of major malnutrition and needed revisional surgery. These should be considered in surgical planning.</div></div>","PeriodicalId":49462,"journal":{"name":"Surgery for Obesity and Related Diseases","volume":"21 2","pages":"Pages 184-193"},"PeriodicalIF":3.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

SOARD Category 1 CME Credit Featured Articles, Volume 21, February 2025

IF 3.5 3区医学 Q1 SURGERY

Surgery for Obesity and Related Diseases

Pub Date : 2025-02-01 DOI: 10.1016/j.soard.2024.12.017

引用次数: 0

Cartoon

IF 3.5 3区医学 Q1 SURGERY

Surgery for Obesity and Related Diseases

Pub Date : 2025-02-01 DOI: 10.1016/j.soard.2024.12.016

引用次数: 0

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Surgery for Obesity and Related Diseases

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀